These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3774829)

  • 1. Effects of nalbuphine alone and in combination with tripelennamine on rewarding brain stimulation thresholds in the rat.
    Unterwald EM; Kornetsky C
    Pharmacol Biochem Behav; 1986 Sep; 25(3):629-32. PubMed ID: 3774829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opiate dependence alters central reward of nalbuphine or pentazocine plus tripelennamine.
    Huston-Lyons D; Bain GT; Kornetsky C
    Eur J Pharmacol; 1989 Oct; 169(1):153-7. PubMed ID: 2599009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of concomitant pentazocine and tripelennamine on brain-stimulation reward.
    Unterwald EM; Kornetsky C
    Pharmacol Biochem Behav; 1984 Dec; 21(6):961-4. PubMed ID: 6335254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tripelennamine: enhancement of brain-stimulation reward.
    Unterwald EM; Kucharski LT; Williams JE; Kornetsky C
    Life Sci; 1984 Jan; 34(2):149-53. PubMed ID: 6607395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nalbuphine, pentazocine, and butorphanol interactions with tripelennamine in mice.
    Schmidt WK; Marynowski ME; Smith C
    NIDA Res Monogr; 1986; 67():145-6. PubMed ID: 3092060
    [No Abstract]   [Full Text] [Related]  

  • 6. The new mixed agonist-antagonist analgesics, nalbuphine and butorphanol, vs. pentazocine: relapse and substitution in morphine-addict rats.
    Steinfels GF; Young GA; Khazan N
    NIDA Res Monogr; 1981 Feb; 34():138-44. PubMed ID: 6783923
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of self-administration.
    Balster RL; Lukas SE
    Drug Alcohol Depend; 1985 Feb; 14(3-4):249-61. PubMed ID: 3888576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cocaine: acute effects on reinforcement thresholds for self-stimulation behavior to the medial forebrain bundle.
    Esposito RU; Motola AH; Kornetsky C
    Pharmacol Biochem Behav; 1978 Apr; 8(4):437-9. PubMed ID: 307772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butorphanol and nalbuphine: a pharmacologic comparison.
    Pallasch TJ; Gill CJ
    Oral Surg Oral Med Oral Pathol; 1985 Jan; 59(1):15-20. PubMed ID: 2983281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-histidine attenuates the effects of pentazocine on rewarding brain-stimulation.
    Rassnick S; Kornetsky C
    Life Sci; 1991; 48(18):1729-36. PubMed ID: 2020256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anesthetic potency of nalbuphine and interaction with morphine in rats.
    DiFazio CA; Moscicki JC; Magruder MR
    Anesth Analg; 1981 Sep; 60(9):629-33. PubMed ID: 6791525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrindole, an opioid delta receptor antagonist, blocks cocaine-induced facilitation of responding for rewarding brain stimulation.
    Reid LD; Hubbell CL; Glaccum MB; Bilsky EJ; Portoghese PS; Porreca F
    Life Sci; 1993; 52(9):PL67-71. PubMed ID: 8382329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opiate mixed agonist-antagonist interactions with histamine antagonists vs. morphine.
    Hui FW; Sun CL; Hanig JP
    Neurobehav Toxicol Teratol; 1985; 7(5):443-7. PubMed ID: 4080063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analgetic effects of an intrathecally administered partial opiate agonist, nalbuphine hydrochloride.
    Schmauss C; Doherty C; Yaksh TL
    Eur J Pharmacol; 1982 Dec; 86(1):1-7. PubMed ID: 6897635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-stimulation reward: a model for the neuronal bases for drug-induced euphoria.
    Kornetsky C
    NIDA Res Monogr; 1985; 62():30-50. PubMed ID: 3935931
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of amfonelic acid alone and in combination with naloxone on brain-stimulation reward.
    Knapp CM; Kornetsky C
    Pharmacol Biochem Behav; 1989 Apr; 32(4):977-82. PubMed ID: 2572008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reinforcing properties of the mixed agonist-antagonist buprenorphine as assessed by brain-stimulation reward.
    Hubner CB; Kornetsky C
    Pharmacol Biochem Behav; 1988 May; 30(1):195-7. PubMed ID: 3174743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.
    Errick JK; Heel RC
    Drugs; 1983 Sep; 26(3):191-211. PubMed ID: 6137354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the calming and sedative effects of nalbuphine and pentazocine for paediatric premedication.
    Rita L; Seleny F; Goodarzi M
    Can Anaesth Soc J; 1980 Nov; 27(6):546-9. PubMed ID: 7013943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.